ResMed Inc.

ResMed Inc. Earnings Recaps

RMD Health Care 4 recaps
Next earnings: February 4, 2027 (estimated) · full calendar
Q1 2027 Oct 31, 2026

ResMed shares fell 9.1% after earnings, despite growth in revenue, gross margin and non-GAAP EPS. The transcript provides no explicit guidance cut or cautious outlook; the likely concern is that 7% core constant-currency revenue growth did not satisfy investors’ expectations.

Key takeaways
  • Q1 revenue grew 7% on a core constant-currency basis; gross margin expanded 50 basis points year over year.
  • Non-GAAP EPS increased 14%. ResMed returned more than $1 billion to shareholders through dividends and share repurchases, funded by MatrixCare divestiture proceeds and cash on hand.
  • The company said its fabric masks showed a 6% increase in therapy adherence versus silicone equivalents; 91% of patients in a ResMed study rated the new AirTouch F40 comfortable or very comfortable at initial fitting.
  • ResMed reported more than 13 million myAir app downloads. Its Dawn digital sleep coach had received more than 2.1 million patient inquiries, up over 40% from the prior quarter.
  • Early real-world data showed Smart Comfort was associated with a 4.3% increase in 30-day compliance versus device default settings.
Q4 2026 Aug 10, 2026

Shares dropped 5.4% as investors reacted negatively to a cautious outlook and signs of deceleration in key metrics, despite management’s positive framing of revenue growth and margin expansion.

Key takeaways
  • Reported 9% headline revenue growth (8% constant currency) for Q4; fiscal 2026 saw 10% total revenue growth.
  • Gross margins improved due to supply chain efficiencies, contributing to 180 basis points of operating margin expansion for the year.
  • Non-GAAP EPS grew 16%, supported by operational execution.
  • Guidance implied a more cautious outlook with emphasis on ongoing operational challenges and transformation work as core markets remain underpenetrated.
  • Increasing patient demographic shifts and evolving market dynamics signal potential headwinds requiring investments in product and marketing adaptation.
Q3 2026 May 3, 2026

Shares fell 3.3% post-earnings, with investor concerns likely centered on the CFO transition rather than the operational results themselves. The retirement of long-tenured CFO Brett Sandercock and the appointment of Aaron Blumer appears to have overshadowed double-digit revenue and EPS growth.

Key takeaways
  • Q3 revenue increased 11% year over year (8% in constant currency).
  • Non-GAAP EPS grew 21% from the prior year.
  • Gross margin expanded 290 basis points year over year, and 50 basis points sequentially.
  • Longstanding CFO Brett Sandercock announced retirement; Aaron Blumer, former Exact Sciences CFO, appointed as successor.
  • Product innovation continued, with strong adoption of fabric-based masks and expansion of the AirSense 11 platform into new international markets.
Q2 2026 Jan 30, 2026

ResMed achieved strong second-quarter results for fiscal year 2026, marked by 11% revenue growth and significant margin expansion, driven by innovation in digital health solutions.

Key takeaways
  • Revenue increased by 11%, with 9% growth on a constant currency basis, reflecting robust demand across product categories.
  • Operating margin improved by 310 basis points year-over-year, with GAAP EPS rising by 16%.
  • Global devices revenue grew high single-digits, while masks and accessories experienced double-digit growth, aided by strategic market initiatives.
  • Successful launch of new fabric masks enhances ResMed's competitive edge in the market.
  • Continued strong cash flow and a solid balance sheet position the company well for future growth and shareholder returns.